Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced...